Molecular Mechanisms of Cereblon-Interacting Small Molecules in Multiple Myeloma Therapy
Source : https://www.mdpi.com/2075-4426/11/11/1185
Thalidomide analogues (or immunomodulatory imide drugs, IMiDs) are cornerstones in the treatment of multiple myeloma (MM). These drugs bind Cereblon (CRBN), a receptor for the Cullin-ring 4 ubiquitin-ligase (CRL4) complex,...
Conclusion/Relevance: Thalidomide analogues (or immunomodulatory imide drugs, IMiDs) are cornerstones in the treatment of multiple myeloma (MM). These drugs bind Cereblon (CRBN), a receptor for the Cullin-ring 4 ubiquitin-ligase (CRL4) complex, to modify its substrate specificity. IMiDs mediate CRBN-dependent engagement and proteasomal...
AntagomiR-19a Induced Better Responsiveness to Bortezomib in Myeloma Cell Lines - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34837676/
2021 Oct;23(5):503-509. doi: 10.22074/cellj.2021.7302. 1 Department of Haematology and Blood Banking, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran. 2 Department of Haematology and Blood Banking, Faculty of Medical...
Conclusion/Relevance: OncomiR-19a, as a biomarker, may induce better responsiveness to BTZ in myeloma cell lines through its targets SOCS3, STAT3 and PTEN. In the future, this biomarker may provide new therapeutic targets for MM.
Isatuximab: Nursing Considerations for Use in the Treatment of Multiple Myeloma - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34800109/
Background: Isatuximab is a CD38 monoclonal antibody approved for use in combination with pomalidomide plus dexamethasone to treat adults with relapsed/refractory multiple myeloma who have received at least two prior...
Conclusions:Nursing care of patients prescribed isatuximab includes monitoring of clinical and laboratory parameters and requires knowledge and management of associated adverse events, including infusion reactions and neutropenia. This information could aid oncology nurses in providing optimal, treatment-specific education to patients and...
Bortezomib in autoimmune hemolytic anemia and beyond - Raffaella Pasquale, Juri Alessandro Giannotta, Wilma Barcellini, Bruno Fattizzo, 2021
Abstract Bortezomib is a first-in-class, potent, selective and reversible proteasome inhibitor approved for the treatment of multiple myeloma (MM) and relapsed/refractory mantle cell lymphoma. In these diseases, bortezomib targets plasma...
0pubmed
In this review, we collected available literature on bortezomib use in AIHA and in other immune-mediated hematologic and non-hematologic diseases. Overall, most experiences highlight bortezomib efficacy even in multi-relapsed/refractory patients and suggest to consider its use in AIHA after rituximab failure.
Salvage therapy with "Dara‐KDT‐P(A)CE" in heavily pretreated, high‐risk, proliferative, relapsed/refractory Multiple Myeloma
Source : https://onlinelibrary.wiley.com/doi/10.1002/hon.2949
Corresponding Author Department of Internal Medicine II, Würzburg University of Hospital, University of Würzburg, Germany Correspondence Xiang Zhou MD, Department of Internal Medicine II Würzburg University Hospital Oberdürrbacher Street 6...